MT-2 (Melanotan II)

What Is Melanotan 2? Structure, Origin and Status

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

MT-2, or Melanotan II, is a cyclic seven-residue peptide analogue of alpha-melanocyte-stimulating hormone at 1024.2 Da. It is unlicensed in every jurisdiction, and it should not be confused with Melanotan I (afamelanotide) which is a different molecule and an approved medicine.

Key facts

Molecular weight
1024.2 Da
Formula
C50H69N15O9
PubChem CID
92432
CAS
121062-08-6
Residues
Seven, cyclic (2-7)
Parent hormone
alpha-MSH, 1,664.9 Da
Melanotan I
Afamelanotide (different, and approved)
MT-2 authorisation
None, anywhere

What it is

The MT2 peptide is a cyclic heptapeptide built as an analogue of alpha-melanocyte-stimulating hormone, written Melanotan II or MT-II in the research literature. Where the parent hormone is thirteen linear residues at 1,664.9 Da, MT-2 compresses the receptor-binding portion into seven residues closed into a ring, at 1024.2 Da.

The confusion that must be cleared first

Melanotan I and Melanotan II are not variants of one product. Melanotan I is afamelanotide, a linear thirteen-residue peptide at 1,646.8 Da, marketed as Scenesse and approved for erythropoietic protoporphyria. Melanotan II is this compound: cyclic, seven residues, 622 Da lighter, and authorised nowhere. Searching a database for melanotan returns the approved one.

Research material referenced

MT-2 10mg, third-party HPLC tested

Buy MT-2 · £24.99

How it relates to KPV

Both derive from alpha-MSH and take opposite halves of it. KPV is the C-terminal tripeptide carrying the anti-inflammatory activity, built specifically to leave the pigmentation behind. MT-2 is built around the melanocortin-receptor-binding core, which is the portion KPV discards. Same parent hormone, opposite design intentions.

Why it is cyclic

A lactam bridge closes the ring between positions 2 and 7. Cyclisation locks conformation, which both improves receptor engagement and removes the free ends that exopeptidases attack. It is one of four separate protease-resistance features built into this molecule.

The safety literature

There is one, and it is not incidental. Reid and colleagues reported atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013. Eijmael and colleagues published on the risks of tanning with this class in the Nederlands Tijdschrift voor Geneeskunde in 2022. Dermatological case reports of an unlicensed injectable compound are the kind of information that should be stated rather than omitted.

Regulatory position

MT-2 holds no marketing authorisation from the MHRA, EMA, FDA or any other regulator. It is supplied here for laboratory research only, and no claim is made about pigmentation, appearance, or any effect in any person.

Frequently asked questions

Is MT-2 the same as Melanotan I?

No. Melanotan I is afamelanotide, a linear 13-residue peptide at 1,646.8 Da and an approved medicine. MT-2 is a cyclic 7-residue peptide at 1024.2 Da, approved nowhere.

How does it relate to KPV?

Both come from alpha-MSH. KPV takes the anti-inflammatory C-terminus; MT-2 is built around the receptor-binding core KPV leaves behind.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More MT-2 (Melanotan II) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.